Reports for the use of TPO-RA in inherited thrombocytopenia, such as MYH9-related disorders or Wiskott–Aldrich syndrome (49, 50), showed benefit on transfusion needs and hemostasis in a total of 80% of patients. The gene discussed is MYH9; the disease is inherited thrombocytopenia.